These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11688535)

  • 1. Limitations of presently available glycopeptides in the treatment of Gram-positive infection.
    Ziglam HM; Finch RG
    Clin Microbiol Infect; 2001; 7 Suppl 4():53-65. PubMed ID: 11688535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides.
    MacGowan AP
    Ther Drug Monit; 1998 Oct; 20(5):473-7. PubMed ID: 9780121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National guidelines for the judicious use of glycopeptides in Belgium.
    Gordts B; Firre E; Jordens P; Legrand JC; Maertens J; Struelens M;
    Clin Microbiol Infect; 2000 Nov; 6(11):585-92. PubMed ID: 11168061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic.
    Goldstein BP; Candiani G; Arain TM; Romanò G; Ciciliato I; Berti M; Abbondi M; Scotti R; Mainini M; Ripamonti F
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1580-8. PubMed ID: 7492108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycopeptide tolerance in bacteria causing endocarditis.
    Perry JD; Jones AL; Gould FK
    J Antimicrob Chemother; 1999 Jul; 44(1):121-4. PubMed ID: 10459820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.
    Arhin FF; Moeck G; Draghi DC; Pillar CM; Sahm DF
    Int J Antimicrob Agents; 2010 Nov; 36(5):474-6. PubMed ID: 20846829
    [No Abstract]   [Full Text] [Related]  

  • 8. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What do I need to know about glycopeptide antibiotics?
    Li S; Starkey ES
    Arch Dis Child Educ Pract Ed; 2016 Dec; 101(6):323-326. PubMed ID: 27389546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
    Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycopeptide resistance in enterococci.
    Méndez-Alvarez S; Pérez-Hernández X; Claverie-Martín F
    Int Microbiol; 2000 Jun; 3(2):71-80. PubMed ID: 11001535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of LY 333328 against anaerobic gram-positive bacteria.
    Sillerström E; Wahlund E; Nord CE
    J Chemother; 1999 Apr; 11(2):90-2. PubMed ID: 10326737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalbavancin: an investigational glycopeptide.
    Guay DR
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):845-52. PubMed ID: 15566329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycopeptide antibiotic biosynthesis.
    Yim G; Thaker MN; Koteva K; Wright G
    J Antibiot (Tokyo); 2014 Jan; 67(1):31-41. PubMed ID: 24220108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oritavancin: a new avenue for resistant Gram-positive bacteria.
    Mercier RC; Hrebickova L
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
    Manfredi R
    Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Daptomycin in the context of antimicrobial resistance in Gram-positive bacteria].
    Candel González FJ
    Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():10-6. PubMed ID: 22541970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycopeptides in clinical development: pharmacological profile and clinical perspectives.
    Van Bambeke F
    Curr Opin Pharmacol; 2004 Oct; 4(5):471-8. PubMed ID: 15351351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of glycopeptide resistance in clinical isolates of gram-positive bacteria.
    Harding I; Lockett A; Brown E
    J Antimicrob Chemother; 1992 Jul; 30(1):105-8. PubMed ID: 1429329
    [No Abstract]   [Full Text] [Related]  

  • 20. The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.
    Kirk M; Hill RL; Casewell MW; Beighton D
    Adv Exp Med Biol; 1997; 418():483-5. PubMed ID: 9331699
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.